A Phase 3 interventional study of Enzalutamide and Placebo in Castration-Resistant Prostate Cancer, sponsored by Pfizer. Completed at 249 sites in 15 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-12-11.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 125 studies testing enzalutamide in Prostatic Neoplasms — 17 open to participants now, 38 under way, 9 of them phase 3. enzalutamide · Prostatic Neoplasms.
Among the 125 studies testing enzalutamide in Prostatic Neoplasms, this one is the 6th largest by enrollment, is the only one that started in 2009, is one of 16 in phase 3, and was the 3rd registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →17 of the 125 studies testing enzalutamide in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Astellas Pharma Global Development, Inc. · Sites in Bulgaria
Ages 50–75 · Men only · Healthy volunteers
University of Michigan Rogel Cancer Center · Sites in United States
Ages 18+ · Men only
Novartis Pharmaceuticals · Sites in United States, Australia, France and 4 more countries
Ages 18+ · Men only
M.D. Anderson Cancer Center · Sites in United States
Ages 18+ · Men only
Alliance for Clinical Trials in Oncology · Sites in United States
Ages 18+
By country, each count listing its studies:
enzalutamide: first FDA approval 2012 (XTANDI), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
125 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 33 · Phase 2 78 · Phase 3 18 · Phase 4 7
First in 2005; this study’s year is marked. 1 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,199 is above the median of 60 across 5,352 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 52 across the 125 interventional studies. Of the 81 that completed or were terminated, 49 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 125 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
42 studies in Prostatic Neoplasms by Pfizer: 3 open now, 8 under way, 5 of them phase 3. Of 33 finished, 28 (85%) have results posted.
Among the 42 studies in Prostatic Neoplasms by Pfizer, this one is the 3rd largest by enrollment of the 33 interventional ones that give a count, is one of 2 that started in 2009, is one of 10 in phase 3, and was the 9th registered.
Pfizer’s Prostatic Neoplasms studies by the year they started, since 1998.
13 of the studies testing enzalutamide in Prostatic Neoplasms that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03903835Phase 3Karolinska InstitutetProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer | 2026-12 |
| NCT02446405Phase 3University of SydneyEnzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer | 2026-12-31 |
| NCT05873192M.D. Anderson Cancer CenterPresurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer | 2026-12-31 |
| NCT03344211University of Southern CaliforniaEnzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer | 2026-12-31 |
| NCT05406999The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNeoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer | 2026-12-31 |
Add all 13 to your calendar (.ics) → With an account.
Among the 125 studies testing enzalutamide in Prostatic Neoplasms, from their registry updates:
Among Pfizer’s 42 in Prostatic Neoplasms:
This tab as a report to print or save as PDF → With an account.
This is a phase 3 study to compare the clinical benefit of MDV3100 versus placebo in patients with castration-resistant prostate cancer who have been previously treated with docetaxel-based chemotherapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Formerly MDV3100
Drug: Enzalutamide
Drug: Placebo
MDV3100, 160 mg orally per day
Also known as: MDV3100, Xtandi
Placebo comparator
Overall Survival
Survival was defined as time from randomization to death due to any cause. The duration of overall survival was right-censored for participants who were lost to follow-up since randomization or not known to have died at the data analysis cut-off date (this included participants who were known to have died after the data analysis cut-off date).
Time frame: During study period (up to 101 months)
Radiographic Progression-free Survival
Radiographic progression-free survival was defined as time from randomization to the earliest objective evidence of radiographic progression or death due to any cause. Participants were assessed for objective disease progression at regularly scheduled visits. The consensus guidelines of the Prostate Cancer Clinical Trials Working Group 2 were taken into consideration for the determination of disease progression. Radiographic disease progression was defined by Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 for soft tissue disease, or the appearance of two or more new bone lesions on bone scan. Progression at the first scheduled reassessment at Week 13 required a confirmatory scan 6 or more weeks later. Participants who did not reach the endpoint were right censored at their last assessment.
Time frame: During DB phase (up to 24 months)
Time to First Skeletal-related Event
The time to first skeletal-related event was defined as time from randomization to the occurrence of the first skeletal-related event. Participants were assessed for skeletal-related events at regularly scheduled visits. A skeletal-related event was defined as radiation therapy or surgery to bone, pathologic bone fracture, spinal cord compression, or change of antineoplastic therapy to treat bone pain. Participants who did not reach the endpoint were right censored at their last assessment.
Time frame: During DB Phase (up to 24 months)
Percentage of Participants Who Were Responders for Functional Assessment of Cancer Therapy-Prostate (FACT-P)
The FACT-P was a 39-item participant questionnaire which assessed physical well-being (7 items), social/family well-being (7 items), emotional well-being (6 items), functional well-being (7 items), and additional prostate cancer specific concerns (12 items). All items were scored from 0 (not at all) to 4 (very much). The sum of scores on all 5 domains constitutes the global FACT-P. The global/total FACT-P score ranged from 0 (worst) to 156 (best), higher scores indicate better health status. Responders were those participants who had a 10-point improvement in their total FACT-P score, as compared with baseline, on two consecutive measurements obtained at least 3 weeks apart.
Time frame: Baseline up to 24 months
Time to Prostate-specific Antigen (PSA) Progression
Time to PSA progression was defined as time from randomization to PSA progression. Participants who did not reach the endpoint were right censored at their last assessment or for participants with no post-baseline PSA assessment, date of randomization. For participants with PSA declines at Week 13, the PSA progression date was defined as the date that a \>=25% increase and an absolute increase of \>=2 nanogram per milliliter (ng/mL) above the nadir was documented, which was confirmed by a second consecutive value obtained 3 or more weeks later (required only if PSA progression did not occur at last PSA assessment). For participants with no PSA declines at Week 13, PSA progression date was defined as the date that a \>=25% increase and an absolute increase of \>=2 ng/mL above the baseline was documented, which was confirmed by a second consecutive value 3 or more weeks later (required only if PSA progression did not occur at last PSA assessment).
Time frame: Baseline and at every study visit from Week 13 while on study drug (up to 24 months)
Percentage of Participants With Pain Palliation
The proportion of participants with pain palliation was assessed for participants with a stable and sufficient pain burden at study entry. Pain burden was measured by question #3 of the Brief Pain Inventory (Short Form). This scale measures pain on a 0 to 10 scale with 0 indicating no pain and 10 indicating pain as bad as you can imagine. Pain palliation at Week 13 was determined for the proportion of men with baseline bone metastasis(es) who had baseline pain attributable to the metastasis(es). Palliation was defined as \>=30% reduction in average pain score at Week 13 compared to baseline without a \>=30% increase in analgesic use.
Time frame: Baseline up to 24 months
Percentage of Participants With Prostate Specific Antigen (PSA) Response
Participants were evaluable for PSA response rate if they had a PSA level measured at baseline and at least 1 post-baseline assessment. Both PSA responses of \> 50% and \> 90% were determined. PSA responses required confirmation with a subsequent assessment that was conducted at least 3 weeks later.
Time frame: During DB phase (up to 24 months)
Percentage of Participants With Soft-tissue Objective Response
The best overall soft tissue response as assessed using RECIST v1.1 during the study was summarized using the investigators' response assessments and also the derived response assessments by treatment group. Only participants with measurable soft tissue disease at screening were included in this analysis. Participants with measurable disease at screening are participants who had at least 1 target lesion identified per RECIST v1.1 at screening. Percentage of participants summarizes the number of participants with complete or partial objective response (%). Soft Tissue assessment based on Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228-247.
Time frame: During DB phase (up to 24 months)
European Quality of Life Five-Domain (EQ-5D) Scale
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility or index score. Five parameters (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) were assessed on 3-point categorical scale (1= no problems, 2= some/moderate problems and 3= severe problem). Score were transformed and resulted in a total EQ-5D score range of 0 (worst imaginable health state) to 100 (best imaginable health state), with higher scores indicating better health and quality of life.
Time frame: Week 13
Percentage of Participants With Circulating Tumor Cell (CTC) Conversion
CTC conversion was assessed for participants with baseline CTC counts of greater than or equal to (\>=) 5 cells per 7.5 milliliter (mL) of blood. A CTC conversion was defined as a decline in the CTC count to less than (\<) 5 cells per 7.5 mL of blood. In this outcome measure percentage of participants with CTC conversion was reported.
Time frame: Baseline up to 24 months
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
AE: any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE: AE resulting in any of following outcomes or deemed significant and jeopardized participants or required treatment to prevent other AE outcomes for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. TEAEs were events which occurred between first dose of study drug and up to the safety follow-up visit or the initiation of another anti-neoplastic therapy, whichever occurred first (up to 101 months). AEs included both serious and non-serious AEs. Clinically significant physical examination abnormalities were reported as AEs. Unscheduled visit was performed at any time during the study whenever necessary to assess for or follow-up on AEs, at the participant's request or if deemed necessary by the investigator.
Time frame: Baseline, up to the safety follow-up visit or unscheduled visit or the initiation of another anti-neoplastic therapy whichever occurred first (up to 101 months)
Number of Participants With Clinically Significant Changes in Vital Signs
Criteria for abnormalities in vital signs included: sitting/supine systolic blood pressure (SBP) values: absolute result greater than (\>) 180 millimeter of mercury (mmHg) and \>40 mmHg increase from baseline (BL) and less than (\<) 90 mmHg and \>30 mmHg decrease from BL; diastolic blood pressure (DBP) values: absolute result \>105 mmHg and \>30 mmHg increase from BL and absolute result \< 50 mmHg and \>20 mmHg decrease from BL; any abnormalities in SBP or DBP; heart rate values: absolute result \> 120 beats per minute (bpm) and \>30 bpm increase from BL and absolute result \< 50 bpm and \>20 bpm decrease from BL or any abnormalities in heart rate. Unscheduled visit was performed at any time during the study whenever necessary to assess for or follow-up on AEs, at the participant's request or if deemed necessary by the investigator.
Time frame: Baseline, up to the safety follow-up visit or unscheduled visit or the initiation of another anti-neoplastic therapy whichever occurred first (up to 101 months)
Number of Participants With Any Newly Clinically Significant Abnormal Finding in Electrocardiogram (ECG)
Any new post baseline abnormality was defined as any abnormal ECG finding that appeared after baseline assessment which was not seen at the screening or baseline ECG assessment. Where, criteria of abnormality was QTcF interval \> 470 millisecond (msec). Participants were counted once only for a specific abnormality. This outcome measure was planned to be analysed in double blind phase only. Unscheduled visit was performed at any time during the study whenever necessary to assess for or follow-up on AEs, at the participant's request or if deemed necessary by the investigator.
Time frame: Baseline, up to the end of DB phase or unscheduled visit (up to 24 months)
Number of Participants With Grade 3/4 Post-Baseline Laboratory Toxicity (Hematology and Chemistry)
Laboratory parameters included hematological and chemistry parameters. Chemistry parameters included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bilirubin, calcium, creatine kinase, creatinine, glucose, magnesium, phosphate, potassium and sodium. Hematology parameters included haemoglobin, leukocytes, lymphocytes, neutrophils and platelet. Test abnormalities were graded by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03 as Grade 3= severe and Grade 4= life-threatening or disabling. Only categories with at least 1 participant with abnormality are reported in this outcome measure. Unscheduled visit was performed at any time during the study whenever necessary to assess for or follow-up on AEs, at the participant's request or if deemed necessary by the investigator.
Time frame: Baseline, up to the safety follow-up visit or unscheduled visit or the initiation of another anti-neoplastic therapy whichever occurred first (up to 101 months)
A total of 1199 participants were enrolled and randomized for double-blind (DB) phase. Out of which, 159 participants entered the optional open-label extension (OLE) phase.
| Milestone | Enzalutamide | Placebo |
|---|---|---|
| Started | 800 | 399 |
| Completed | 109 | 50 |
| Not completed | 691 | 349 |
| Withdrew: Lost to follow-up | 5 | 2 |
| Withdrew: Death | 561 | 298 |
| Withdrew: Withdrawal by subject | 16 | 7 |
| Withdrew: Study terminated by sponsor | 108 | 42 |
| Withdrew: Other | 1 | 0 |
| Milestone | Enzalutamide | Placebo |
|---|---|---|
| Started | 109 | 50 |
| Completed | 0 | 0 |
| Not completed | 109 | 50 |
| Withdrew: Death | 14 | 21 |
| Withdrew: Study terminated by sponsor | 78 | 26 |
| Withdrew: Other | 15 | 2 |
| Withdrew: Withdrawal by subject | 2 | 1 |
Survival was defined as time from randomization to death due to any cause. The duration of overall survival was right-censored for participants who were lost to follow-up since randomization or not known to have died at the data analysis cut-off date (this included participants who were known to have died after the data analysis cut-off date).
| Months | Enzalutamide | Placebo |
|---|---|---|
| Overall Survival | 18.4 (17.3 to NA) | 13.6 (11.3 to 15.8) |
Radiographic progression-free survival was defined as time from randomization to the earliest objective evidence of radiographic progression or death due to any cause. Participants were assessed for objective disease progression at regularly scheduled visits. The consensus guidelines of the Prostate Cancer Clinical Trials Working Group 2 were taken into consideration for the determination of disease progression. Radiographic disease progression was defined by Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 for soft tissue disease, or the appearance of two or more new bone lesions on bone scan. Progression at the first scheduled reassessment at Week 13 required a confirmatory scan 6 or more weeks later. Participants who did not reach the endpoint were right censored at their last assessment.
| Months | Enzalutamide | Placebo |
|---|---|---|
| Radiographic Progression-free Survival | 8.3 (8.2 to 9.4) | 2.9 (2.8 to 3.4) |
The time to first skeletal-related event was defined as time from randomization to the occurrence of the first skeletal-related event. Participants were assessed for skeletal-related events at regularly scheduled visits. A skeletal-related event was defined as radiation therapy or surgery to bone, pathologic bone fracture, spinal cord compression, or change of antineoplastic therapy to treat bone pain. Participants who did not reach the endpoint were right censored at their last assessment.
| Months | Enzalutamide | Placebo |
|---|---|---|
| Time to First Skeletal-related Event | 16.7 (14.6 to 19.1) | 13.3 (9.9 to NA) |
The FACT-P was a 39-item participant questionnaire which assessed physical well-being (7 items), social/family well-being (7 items), emotional well-being (6 items), functional well-being (7 items), and additional prostate cancer specific concerns (12 items). All items were scored from 0 (not at all) to 4 (very much). The sum of scores on all 5 domains constitutes the global FACT-P. The global/total FACT-P score ranged from 0 (worst) to 156 (best), higher scores indicate better health status. Responders were those participants who had a 10-point improvement in their total FACT-P score, as compared with baseline, on two consecutive measurements obtained at least 3 weeks apart.
| Percentage of participants | Enzalutamide | Placebo |
|---|---|---|
| Percentage of Participants Who Were Responders for Functional Assessment of Cancer Therapy-Prostate (FACT-P) | 43.2 (39.3 to 47.1) | 18.3 (13.8 to 23.6) |
Time to PSA progression was defined as time from randomization to PSA progression. Participants who did not reach the endpoint were right censored at their last assessment or for participants with no post-baseline PSA assessment, date of randomization. For participants with PSA declines at Week 13, the PSA progression date was defined as the date that a \>=25% increase and an absolute increase of \>=2 nanogram per milliliter (ng/mL) above the nadir was documented, which was confirmed by a second consecutive value obtained 3 or more weeks later (required only if PSA progression did not occur at last PSA assessment). For participants with no PSA declines at Week 13, PSA progression date was defined as the date that a \>=25% increase and an absolute increase of \>=2 ng/mL above the baseline was documented, which was confirmed by a second consecutive value 3 or more weeks later (required only if PSA progression did not occur at last PSA assessment).
| Months | Enzalutamide | Placebo |
|---|---|---|
| Time to Prostate-specific Antigen (PSA) Progression | 8.3 (5.8 to 8.3) | 3.0 (2.9 to 3.7) |
The proportion of participants with pain palliation was assessed for participants with a stable and sufficient pain burden at study entry. Pain burden was measured by question #3 of the Brief Pain Inventory (Short Form). This scale measures pain on a 0 to 10 scale with 0 indicating no pain and 10 indicating pain as bad as you can imagine. Pain palliation at Week 13 was determined for the proportion of men with baseline bone metastasis(es) who had baseline pain attributable to the metastasis(es). Palliation was defined as \>=30% reduction in average pain score at Week 13 compared to baseline without a \>=30% increase in analgesic use.
| Percentage of participants | Enzalutamide | Placebo |
|---|---|---|
| Percentage of Participants With Pain Palliation | 44.9 (30.7 to 59.8) | 6.7 (0.2 to 31.9) |
Participants were evaluable for PSA response rate if they had a PSA level measured at baseline and at least 1 post-baseline assessment. Both PSA responses of \> 50% and \> 90% were determined. PSA responses required confirmation with a subsequent assessment that was conducted at least 3 weeks later.
| Percentage of participants | Enzalutamide | Placebo |
|---|---|---|
| Decline >=50% from baseline | 54 | 2 |
| Decline >=90% from baseline | 25 | 1 |
The best overall soft tissue response as assessed using RECIST v1.1 during the study was summarized using the investigators' response assessments and also the derived response assessments by treatment group. Only participants with measurable soft tissue disease at screening were included in this analysis. Participants with measurable disease at screening are participants who had at least 1 target lesion identified per RECIST v1.1 at screening. Percentage of participants summarizes the number of participants with complete or partial objective response (%). Soft Tissue assessment based on Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228-247.
| Percentage of participants | Enzalutamide | Placebo |
|---|---|---|
| Percentage of Participants With Soft-tissue Objective Response | 29 | 4 |
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility or index score. Five parameters (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) were assessed on 3-point categorical scale (1= no problems, 2= some/moderate problems and 3= severe problem). Score were transformed and resulted in a total EQ-5D score range of 0 (worst imaginable health state) to 100 (best imaginable health state), with higher scores indicating better health and quality of life.
| units on a scale | Enzalutamide | Placebo |
|---|---|---|
| European Quality of Life Five-Domain (EQ-5D) Scale | 67.2 ± 19.29 | 60.0 ± 19.26 |
CTC conversion was assessed for participants with baseline CTC counts of greater than or equal to (\>=) 5 cells per 7.5 milliliter (mL) of blood. A CTC conversion was defined as a decline in the CTC count to less than (\<) 5 cells per 7.5 mL of blood. In this outcome measure percentage of participants with CTC conversion was reported.
| percentage of participants | Enzalutamide | Placebo |
|---|---|---|
| Percentage of Participants With Circulating Tumor Cell (CTC) Conversion | 48 (39.09 to 57.07) | 9.7 (3.63 to 19.88) |
AE: any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE: AE resulting in any of following outcomes or deemed significant and jeopardized participants or required treatment to prevent other AE outcomes for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. TEAEs were events which occurred between first dose of study drug and up to the safety follow-up visit or the initiation of another anti-neoplastic therapy, whichever occurred first (up to 101 months). AEs included both serious and non-serious AEs. Clinically significant physical examination abnormalities were reported as AEs. Unscheduled visit was performed at any time during the study whenever necessary to assess for or follow-up on AEs, at the participant's request or if deemed necessary by the investigator.
| Participants | Enzalutamide | Placebo: DB Phase | Placebo (DB) /Enzalutamide 160 mg (OLE) Phase |
|---|---|---|---|
| AEs | 789 | 390 | 48 |
| SAEs | 319 | 155 | 25 |
Criteria for abnormalities in vital signs included: sitting/supine systolic blood pressure (SBP) values: absolute result greater than (\>) 180 millimeter of mercury (mmHg) and \>40 mmHg increase from baseline (BL) and less than (\<) 90 mmHg and \>30 mmHg decrease from BL; diastolic blood pressure (DBP) values: absolute result \>105 mmHg and \>30 mmHg increase from BL and absolute result \< 50 mmHg and \>20 mmHg decrease from BL; any abnormalities in SBP or DBP; heart rate values: absolute result \> 120 beats per minute (bpm) and \>30 bpm increase from BL and absolute result \< 50 bpm and \>20 bpm decrease from BL or any abnormalities in heart rate. Unscheduled visit was performed at any time during the study whenever necessary to assess for or follow-up on AEs, at the participant's request or if deemed necessary by the investigator.
| Participants | Enzalutamide | Placebo: DB Phase | Placebo (DB) /Enzalutamide 160 mg (OLE) Phase |
|---|---|---|---|
| SBP: >180 mmHg and >40 mmHg Increase from BL | 28 | 7 | 1 |
| SBP: < 90 mmHg and >30 mmHg Decrease from BL | 13 | 5 | 0 |
| DBP: >105 mmHg and >30 mmHg Increase from BL | 5 | 2 | 0 |
| DBP: < 50 mmHg and >20 mmHg Decrease from BL | 13 | 3 | 1 |
| Any abnormalities in SBP or DBP | 52 | 16 | 2 |
| Heart Rate: > 120 bpm and >30 bpm Increase from BL | 7 | 5 | 0 |
| Heart Rate: < 50 bpm and >20 bpm Decrease from BL | 18 | 1 | 0 |
| Any abnormalities in Heart Rate | 25 | 6 | 0 |
Any new post baseline abnormality was defined as any abnormal ECG finding that appeared after baseline assessment which was not seen at the screening or baseline ECG assessment. Where, criteria of abnormality was QTcF interval \> 470 millisecond (msec). Participants were counted once only for a specific abnormality. This outcome measure was planned to be analysed in double blind phase only. Unscheduled visit was performed at any time during the study whenever necessary to assess for or follow-up on AEs, at the participant's request or if deemed necessary by the investigator.
| Participants | Enzalutamide | Placebo: DB Phase |
|---|---|---|
| Number of Participants With Any Newly Clinically Significant Abnormal Finding in Electrocardiogram (ECG) | 28 | 13 |
Laboratory parameters included hematological and chemistry parameters. Chemistry parameters included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bilirubin, calcium, creatine kinase, creatinine, glucose, magnesium, phosphate, potassium and sodium. Hematology parameters included haemoglobin, leukocytes, lymphocytes, neutrophils and platelet. Test abnormalities were graded by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03 as Grade 3= severe and Grade 4= life-threatening or disabling. Only categories with at least 1 participant with abnormality are reported in this outcome measure. Unscheduled visit was performed at any time during the study whenever necessary to assess for or follow-up on AEs, at the participant's request or if deemed necessary by the investigator.
| Participants | Enzalutamide | Placebo: DB Phase | Placebo (DB) /Enzalutamide 160 mg (OLE) Phase |
|---|---|---|---|
| Alanine Aminotransferase:High | 2 | 2 | 1 |
| Albumin: Low | 7 | 3 | 0 |
| Alkaline Phosphatase: High | 102 | 74 | 3 |
| Aspartate Aminotransferase: High | 3 | 4 | 1 |
| Bilirubin: High | 2 | 0 | 0 |
| Calcium: Low | 14 | 15 | 1 |
| Calcium: High | 1 | 0 | 0 |
| Creatine Kinase: High | 4 | 2 | 0 |
| Creatinine: High | 0 | 2 | 0 |
| Glucose: High | 17 | 10 | 1 |
| Magnesium: Low | 0 | 1 | 0 |
| Magnesium: High | 1 | 1 | 0 |
| Phosphate: Low | 28 | 10 | 2 |
| Potassium: Low | 7 | 4 | 1 |
| Potassium: High | 2 | 3 | 0 |
| Sodium: Low | 19 | 13 | 0 |
| Sodium: High | 0 | 1 | 0 |
| Hemoglobin: Low | 38 | 20 | 4 |
| Hemoglobin: High | 1 | 0 | 0 |
| Leukocytes: Low | 8 | 1 | 1 |
| Lymphocytes: Low | 80 | 48 | 5 |
| Neutrophils: Low | 10 | 0 | 1 |
| Platelet; Low | 4 | 4 | 0 |
Collected over Baseline, up to the safety follow-up visit or unscheduled visit or the initiation of another anti-neoplastic therapy whichever occurred first (up to 101 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Enzalutamide: DB + OLE Phase | — | 319/800 (39.9%) | 784/800 (98%) |
| Placebo: DB Phase | — | 155/399 (38.8%) | 385/399 (96.5%) |
| Placebo (DB) /Enzalutamide 160 mg (OLE) Phase | — | 25/50 (50%) | 47/50 (94%) |
| Event | Enzalutamide: DB + OLE Phase | Placebo: DB Phase | Placebo (DB) /Enzalutamide 160 mg (OLE) Phase |
|---|---|---|---|
| Spinal cord compressionNervous system disorders | 54/800 | 15/399 | 3/50 |
| General physical health deteriorationGeneral disorders | 22/800 | 8/399 | 3/50 |
| Metastatic painNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 18/800 | 3/399 | 3/50 |
| AnaemiaBlood and lymphatic system disorders | 22/800 | 12/399 | 2/50 |
| Cardiac failureCardiac disorders | 3/800 | 2/399 | 2/50 |
| ConvulsionNervous system disorders | 4/800 | 0/399 | 2/50 |
| Disease progressionGeneral disorders | 1/800 | 0/399 | 2/50 |
| HaematuriaRenal and urinary disorders | 18/800 | 5/399 | 1/50 |
| VomitingGastrointestinal disorders | 3/800 | 8/399 | 1/50 |
| Urinary retentionRenal and urinary disorders | 7/800 | 8/399 | 0/50 |
| Event | Enzalutamide: DB + OLE Phase | Placebo: DB Phase | Placebo (DB) /Enzalutamide 160 mg (OLE) Phase |
|---|---|---|---|
| NauseaGastrointestinal disorders | 276/800 | 166/399 | 16/50 |
| FatigueGeneral disorders | 280/800 | 115/399 | 14/50 |
| Decreased appetiteMetabolism and nutrition disorders | 246/800 | 121/399 | 9/50 |
| Back painMusculoskeletal and connective tissue disorders | 225/800 | 91/399 | 9/50 |
| ConstipationGastrointestinal disorders | 209/800 | 109/399 | 7/50 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 182/800 | 71/399 | 2/50 |
| DiarrhoeaGastrointestinal disorders | 180/800 | 70/399 | 9/50 |
| AnaemiaBlood and lymphatic system disorders | 123/800 | 70/399 | 11/50 |
| VomitingGastrointestinal disorders | 141/800 | 84/399 | 8/50 |
| Hot flushVascular disorders | 165/800 | 41/399 | 1/50 |
Intent-to-treat population (ITT) included all participants who were randomized into the study.
| Age, Categorical(Participants) | Enzalutamide | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 232 | 130 | 362 |
| >=65 years | 568 | 269 | 837 |
| Age, Continuous(years) | Enzalutamide | Placebo | Total |
|---|---|---|---|
| Mean | 68.8 ± 7.96 | 68.6 ± 8.39 | 68.7 ± 8.11 |
| Sex: Female, Male(Participants) | Enzalutamide | Placebo | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 800 | 399 | 1199 |
| Ethnicity (NIH/OMB)(Participants) | Enzalutamide | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 32 | 23 | 55 |
| Not Hispanic or Latino | 768 | 376 | 1144 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Enzalutamide | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 1 | 2 |
| Asian | 5 | 8 | 13 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Black or African American | 27 | 20 | 47 |
| White | 745 | 366 | 1111 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 21 | 4 | 25 |
| Region of Enrollment(Participants) | Enzalutamide | Placebo | Total |
|---|---|---|---|
| United States | 181 | 107 | 288 |
| Spain | 23 | 13 | 36 |
| Austria | 15 | 10 | 25 |
| Chile | 6 | 5 | 11 |
| United Kingdom | 82 | 50 | 132 |
| Italy | 20 | 10 | 30 |
| France | 193 | 80 | 273 |
| Canada | 82 | 25 | 107 |
| Argentina | 7 | 3 | 10 |
| Belgium | 27 | 18 | 45 |
| Poland | 7 | 4 | 11 |
| Australia | 60 | 33 | 93 |
| South Africa | 3 | 3 | 6 |
| Germany | 62 | 24 | 86 |
| Netherlands | 32 | 14 | 46 |
Showing the first 100 of 249 sites across 15 countries. Choose a country and city above to see the rest.
Ran from Sep 2009 to primary completion in Sep 2011, 23 months.
Results were first posted in Oct 2012, 1 year 1 month after primary completion.
Of 126 industry-sponsored phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 53. This study's 23 months is below that.
Counting every sponsor, half of 265 studies reached it within 57 months; a quarter within 31 and three quarters within 100.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Enzalutamide